CytoDyn
1111 Main Street
Suite 660
Vancouver
Washington
98660
United States
Website: http://www.cytodyn.com/
308 articles about CytoDyn
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 2, 2020.
-
Clinical Catch-Up: March 23-27
3/30/2020
Although some clinical trials are being slowed or halted, others are reporting out data. Here’s a look. -
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 30, 2020.
-
A summary of daily biopharma industry news. Please check out stories that are trending on March 27, 2020.
-
Clinical Catch-Up: March 9-13
3/16/2020
Although news of the COVID-19 pandemic has tended to dominate the news cycle, including for the biopharma industry, there were a number of clinical trial announcements last week. Here’s a look. -
Clinical Catch-Up: March 2-6
3/9/2020
It was a relatively quiet week for clinical trial announcements. Here’s a look. -
Clinical Catch-Up: February 17-21
2/24/2020
Mid-February had a solid number of clinical trial announcements. Here’s a look. -
Clinical Catch-Up: February 10-14
2/17/2020
It was a very busy week for clinical trial news. Here’s a look. -
Clinical Catch-Up: February 3-7, 2020
2/10/2020
Although it was a relatively slow week for clinical trial updates, there were still a number of announcements. Here’s a look. -
Clinical Catch-Up: January 27-31
2/3/2020
It was another busy week for clinical trial updates. Here’s a look. -
Leronlimab Under Evaluation for Potential Treatment of CoronavirusCytoDyn and IncellDX in discussions with potential partners about the use of leronlimab to treat 2019 Novel Coronavirus (2019-nCoV)
1/28/2020
CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that it is exploring leronlimab as a potential treatment for patients infected with the 2019 Novel Coronavirus (2019-nCoV), a rapidly spreading virus and potential worldwide emergency.
-
Clinical Catch-Up: Jan 20-24
1/27/2020
The week after the JP Morgan Healthcare Conference tends to be slower than the week of, and last week was no outlier. Still, there were clinical trial updates. Here’s a look. -
BioSpace Movers & Shakers, Jan. 24
1/24/2020
Pharma and life sciences companies strengthen their leadership and boards with this week's appointments. -
CytoDyn Appoints Maura Fleming as Vice President, General Counsel and Corporate Secretary
1/23/2020
CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced the appointment of Maura Fleming as the Company’s vice president, general counsel and corporate secretary
-
CytoDyn Files for Breakthrough Therapy Designation with the FDA for the Use of Leronlimab for the Treatment of Metastatic Triple-Negative Breast Cancer
1/13/2020
The BTD filing is based on data from the first patient in the Company’s mTNBC Phase 1b/2 trial and an additional single-patient trial under an emergency investigational new drug protocol evaluating leronlimab for the treatment of HER2+ metastatic, stage 4, breast cancer
-
Clinical Catch-Up: December 23-27
12/30/2019
With the holidays, it’s not surprising that it was a quiet week for clinical trial news. Nonetheless, some companies did have clinical trial stories to report. Here’s a look. -
CytoDyn Signs Definitive Agreements with Vyera Pharmaceuticals to Commercialize Leronlimab in the U.S. for the Treatment of HIV
12/17/2019
In exchange for the exclusive right to market and distribute leronlimab in the U.S. for HIV-related indications, Vyera will pay upfront and regulatory and sales-based milestone payments of up to $87.5 million, as well as a royalty of 50 percent on net sales. Vyera will also make an investment in CytoDyn of $4 million in the form of registered CytoDyn common stock
-
CytoDyn to Hold Investment Community Conference Call on December 17, 2019
12/11/2019
A live audio webcast may also be accessed via CytoDyn’s corporate website at www.cytodyn.com under the Investors section/IR Calendar and will be archived for 30 days.
-
Clinical Catch-Up: December 2-5
12/9/2019
It was, as usual, a pretty busy week in clinical trial news. Here’s a look.